• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Five-year prospective multi-center cohort study of patients with giant cell arteritis in Greece.希腊巨细胞动脉炎患者的五年前瞻性多中心队列研究。
Mediterr J Rheumatol. 2018 Jun 29;29(2):103-105. doi: 10.31138/mjr.29.2.103. eCollection 2018 Jun.
2
Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.是否存在糖皮质激素抵抗性大血管血管炎(巨细胞动脉炎和 Takayasu 动脉炎),如何实现缓解?文献综述。
Clin Exp Rheumatol. 2012 Jan-Feb;30(1 Suppl 70):S114-29. Epub 2012 May 11.
3
Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study.巨细胞动脉炎患者的疾病复发:一项前瞻性纵向队列研究。
J Rheumatol. 2015 Jul;42(7):1213-7. doi: 10.3899/jrheum.141347. Epub 2015 Apr 15.
4
Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial.新诊断与复发的巨细胞动脉炎:来自GiACTA试验的基线数据。
Semin Arthritis Rheum. 2017 Apr;46(5):657-664. doi: 10.1016/j.semarthrit.2016.11.002. Epub 2016 Nov 15.
5
Treatment of giant cell arteritis.巨细胞动脉炎的治疗。
Biochem Pharmacol. 2019 Jul;165:230-239. doi: 10.1016/j.bcp.2019.04.027. Epub 2019 Apr 26.
6
Ustekinumab for refractory giant cell arteritis: A prospective 52-week trial.乌司奴单抗治疗难治性巨细胞动脉炎:一项前瞻性 52 周试验。
Semin Arthritis Rheum. 2018 Dec;48(3):523-528. doi: 10.1016/j.semarthrit.2018.04.004. Epub 2018 Apr 22.
7
Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.患有巨细胞动脉炎或多发性肌痛症或两种疾病的患者的长期糖皮质激素治疗:来自国家风湿病学数据库的结果。
Rheumatol Int. 2018 Apr;38(4):569-577. doi: 10.1007/s00296-017-3874-3. Epub 2017 Nov 9.
8
Sustained remission after long-term biological therapy in patients with large vessel vasculitis: an analysis of ten cases.大血管血管炎患者长期生物治疗后的持续缓解:10例分析
Reumatol Clin. 2017 Jul-Aug;13(4):210-213. doi: 10.1016/j.reuma.2016.06.003. Epub 2016 Aug 4.
9
A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis.一项关于巨细胞动脉炎辅助性甲氨蝶呤治疗的多中心、随机、双盲、安慰剂对照试验。
Arthritis Rheum. 2002 May;46(5):1309-18. doi: 10.1002/art.10262.
10
Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis.133例巨细胞动脉炎患者队列中的预后因素及长期演变情况
Clin Exp Rheumatol. 2001 Mar-Apr;19(2):171-6.

引用本文的文献

1
Glucocorticoid discontinuation rate and risk factors for relapses in a contemporary cohort of patients with giant cell arteritis.糖皮质激素停药率及巨细胞动脉炎当代患者复发的危险因素。
Rheumatol Int. 2024 Apr;44(4):603-610. doi: 10.1007/s00296-023-05527-8. Epub 2024 Feb 1.
2
Mediterranean Journal of Rheumatology June 2018 Issue Highlights.《地中海风湿病学杂志》2018年6月刊亮点
Mediterr J Rheumatol. 2018 Jun 29;29(2):65-66. doi: 10.31138/mjr.29.2.65. eCollection 2018 Jun.

本文引用的文献

1
Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis.巨细胞动脉炎(GCA)患者糖皮质激素治疗相关的严重不良反应:一项巢式病例对照分析。
Semin Arthritis Rheum. 2017 Jun;46(6):819-827. doi: 10.1016/j.semarthrit.2016.11.006. Epub 2016 Nov 28.
2
Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review.巨细胞动脉炎与风湿性多肌痛:系统评价。
JAMA. 2016 Jun 14;315(22):2442-58. doi: 10.1001/jama.2016.5444.
3
Incidence of Severe Infections and Infection-Related Mortality During the Course of Giant Cell Arteritis: A Multicenter, Prospective, Double-Cohort Study.巨细胞动脉炎病程中严重感染和感染相关死亡率的发生率:一项多中心、前瞻性、双队列研究。
Arthritis Rheumatol. 2016 Jun;68(6):1477-82. doi: 10.1002/art.39596.
4
Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study.经活检证实的巨细胞动脉炎复发及治疗结果的预测因素:一项回顾性队列研究。
Rheumatology (Oxford). 2016 Feb;55(2):347-56. doi: 10.1093/rheumatology/kev348. Epub 2015 Sep 18.
5
Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients.巨细胞动脉炎患者的复发情况:106例纵向随访队列中的患病率、特征及相关临床发现
Medicine (Baltimore). 2014 Jul;93(5):194-201. doi: 10.1097/MD.0000000000000033.
6
Epidemiology of giant cell arteritis and polymyalgia rheumatica.巨细胞动脉炎和风湿性多肌痛的流行病学
Arthritis Rheum. 2009 Oct 15;61(10):1454-61. doi: 10.1002/art.24459.
7
Prevalence of rheumatic diseases in Greece: a cross-sectional population based epidemiological study. The ESORDIG Study.希腊风湿性疾病的患病率:一项基于人群的横断面流行病学研究。ESORDIG研究。
J Rheumatol. 2003 Jul;30(7):1589-601.

希腊巨细胞动脉炎患者的五年前瞻性多中心队列研究。

Five-year prospective multi-center cohort study of patients with giant cell arteritis in Greece.

作者信息

Tsalapaki Christina, Nikitopoulou Eleni, Boki Kyriaki A, Boumpas Dimitrios, Sfikakis Petros P, Vosvotekas Georgios, Voulgari Paraskevi V, Vassilopoulos Dimitrios

机构信息

Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.

Clinical Immunology-Rheumatology Unit, 2 Department of Medicine and Laboratory, Hippokration General Hospital, Athens, Greece.

出版信息

Mediterr J Rheumatol. 2018 Jun 29;29(2):103-105. doi: 10.31138/mjr.29.2.103. eCollection 2018 Jun.

DOI:10.31138/mjr.29.2.103
PMID:32185310
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7046071/
Abstract

Giant cell arteritis (GCA) is the most common systemic vasculitis in the aged population associated with significant morbidity due to the long term administration of corticosteroids and the presence of various comorbidities. Data regarding its current treatment modalities, comorbidities, morbidity and mortality in Greece are limited. In this multi-center, prospective study that begun at the end of 2015 patients with newly diagnosed GCA according to the modified 1990 ACR criteria, as well as individuals with established or relapsing disease have been included. During the 1 phase of the study that is still ongoing, data are being collected concerning demographic and clinical characteristics of the patients, treatment at the onset of the disease and at relapses, relapses, adverse events of therapy, comorbidities, hospitalizations and deaths. During the 2 and 3 phase of the study patients will be reevaluated 2 and 5 years after their 1st evaluation. The study is expected to provide valuable data regarding the current clinical characteristics, comorbidities, therapeutic regimens used, relapse rate, morbidity and mortality of patients with GCA.

摘要

巨细胞动脉炎(GCA)是老年人群中最常见的系统性血管炎,由于长期使用皮质类固醇以及存在各种合并症,其发病率较高。关于希腊目前对其治疗方式、合并症、发病率和死亡率的数据有限。在这项始于2015年末的多中心前瞻性研究中,纳入了根据1990年美国风湿病学会(ACR)修订标准新诊断的GCA患者,以及患有已确诊疾病或复发疾病的个体。在仍在进行的研究的第1阶段,正在收集有关患者的人口统计学和临床特征、疾病发作时及复发时的治疗、复发情况、治疗不良事件、合并症、住院情况和死亡情况的数据。在研究的第2和第3阶段,患者将在首次评估后的2年和5年进行重新评估。该研究预计将提供有关GCA患者当前临床特征、合并症、使用的治疗方案、复发率、发病率和死亡率的有价值数据。